Comparison of argatroban versus citrate anticoagulation in continuous renal replacement therapy for patients with acute severe pancreatitis
LIU Jing
YANG Yuqiang
XU Zihui
HOU Yihan
PAN Mandong
LIN Jiyan
Abstract：Objective To compare the efficacy of argatroban versus citrate anticoagulation in continuous renal replace-ment therapy(CRRT)for patients with severe acute pancreatitis(SAP).Methods A retrospective study was conducted on 80 SAP patients,who were divided into the argatroban group of 35 cases and citrate group of 45 cases based on the anticoagu-lant used during CRRT.The study compared the single filter lifespan,coagulation function parameters[activated partial thromboplastin time(APTT),prothrombin time(PT),fibrinogen(FIB),and D-dimer(D-D)],serum electrolyte levels[sodi-um ion(Na+),potassium ion(K+),and calcium ion(Ca2+)],and economic indicators(hospital stay duration,total hospitaliza-tion cost,daily cost)before and within 24 h after CRRT.Results The single filter lifespan in the argatroban group was short-er than that in the citrate group(P<0.05).After treatment,D-D levels increased in both groups compared to baseline(both P<0.05).The citrate group exhibited lower APTT and PT levels but a higher D-D level than the argatroban group(all P<0.05).After treatment,the citrate group showed a reduced K+level compared to the baseline(P<0.05),and the Ca2+lev-el was lower in the citrate group than in the argatroban group(P<0.05).The argatroban group had shorter hospital stay,low-er total hospitalization cost,and lower daily cost than the citrate group(all P<0.05).Conclusion For SAP patients under-going CRRT,argatroban demonstrates superior anticoagulant efficacy and cost-effectiveness in comparison with citrate.
Keywords：severe acute pancreatitisargatrobancitratecontinuous renal replacement therapyanticoagulant efficacy
Publication Date：2025-05-25
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 76-80 )